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Deaths from sexually transmitted diseases
(STDs) often occur long after acute infection,
making their incidence difficult to estimate.1---3
Some infections, such as syphilis, may directly
result in death. By contrast, human papilloma
virus (HPV), HIV, and hepatitis more com-
monly cause death because of secondary se-
quelae. Genital herpes, gonorrheal infection,
and chlamydial infection may cause death from
primary infection (e.g., disseminated herpes
simplex virus or pelvic inflammatory disease
[PID]) or secondary sequelae (e.g., ectopic
pregnancy). Because death certificates usually
list only the prevalent conditions, STDs are
often not recorded on death certificates. In
addition, some causes of death, such as liver
cancer, may or may not be STD related. STD-
related deaths cannot always be counted di-
rectly; therefore, direct and indirect methods
of estimation must be used.
The methodology for estimating STD-
related mortality in women in the United
States has evolved. Early estimates used mea-
sures of reproductive health mortality.1 Sub-
sequently, a more comprehensive approach
used direct and indirect measures of deaths
from all STD-related diseases.2 Most recently,
disability-adjusted life-years lost because of
sexual behaviors were found to be threefold
higher in the United States than in other
developed countries. Women carry a dispro-
portionately high proportion of the health
burden.3
Between 1955 and 1975, STDs such as
syphilis and PID were responsible for 20% to
30% of reproductive mortality among women
aged 15 to 44 years.1 Since then, mortality
from syphilis and PID has decreased. Cervical
carcinoma, HIV, and viral hepatitis infection
were the top 3 contributors to STD-related
mortality among all women older than 15
years as of 1992.2 I have updated the esti-
mated annual STD-related mortality among
reproductive-aged women in the United States
for 1999 to 2010.
METHODS
I calculated a crude mortality rate (deaths per
100 000 reproductive-aged women per year)
by dividing the total number of deaths from
each STD by the population of reproductive-aged
women for that year. I identified STD-related
mortality with the Multiple Cause of Death data-
base available from the Centers for Disease
Control and Prevention (CDC) National Center for
Health Statistics.4 This database provides access
to death certificate data for US residents. At the
time of death, a single International Classification
of Diseases (ICD)5 code is provided to define a
single cause of death for each decedent. If multiple
causes of death are identified, up to 30 ICD codes
are listed under multiple cause of death.
I identified the total number of deaths for
reproductive-aged women (aged 15---44 years)
for whom a STD-related etiology was identified
as an underlying cause of death between 1999
and 2010. I identified STDs and sequelae
with the ICD-10 codes5 listed in Table 1. For
infections or sequelae that are partially sexually
transmitted, I derived a percentage attributable to
sexual transmission from estimates from the
literature, consistent with previous mortality
analyses (Table 1).1,2 I considered the following
to be universally transmitted by sexual contact
in reproductive-aged women: Neisseria gonor-
rheae, Chlamydia trachomatis, genital herpes
simplex virus, HPV, and syphilis. I identified
the following as partially sexually transmitted:
HIV, hepatitis B virus, and hepatitis C virus. I
identified the following partially STD-related
sequelae: PID, ectopic pregnancy, chronic liver
disease, hepatocellular carcinoma, and cervical,
vulvar, and vaginal carcinoma.
I estimated the number of reproductive-aged
women each year from 1999 to 2010 from the
US Census Bureau.4 If the number of deaths
was too small to calculate a reliable mortality
rate, I reported the total number of deaths.
An independent reviewer repeated the data
extraction and analysis to confirm accuracy.
RESULTS
Between 1999 and 2010, an estimated
31 351 STD-related deaths occurred among
Objectives. I estimated the sexually transmitted disease–related mortality
among US reproductive-aged women from 1999 to 2010.
Methods. I estimated mortality from National Center for Health Statistics’
Multiple Cause of Death data. I defined reproductive age as 15 to 44 years. For
diseases partially caused by sexual transmission, I estimated the proportion
attributable to sexual transmission from the literature. To calculate mortality
rates, I estimated number of deaths from each disease and Census Bureau
population for reproductive-aged women for 1999 to 2010.
Results. From1999 to 2010, the cumulative sexually transmitted disease–related
mortality rate decreased by 49%, from 5.3 to 2.7 deaths per 100 000. The primary
contributors were HIV and human papilloma virus infections. Mortality from sexually
transmitted HIV infection decreased by 62%, from 3.4 to 1.3 deaths per 100 000.
Mortality from human papilloma virus–associated gynecologic cancers decreased
by 19%, from 1.6 deaths per 100 000 in 1999 to 1.3 deaths per 100 000 in 2010.
Conclusions. Screening and treatment for sexually transmitted diseases may
reduce mortality. Research is needed to determine whether sexually transmitted
disease–relatedmorbidity among reproductive-agedwomen has decreased over
the past decade. (Am J Public Health. 2014;104:e101–e105. doi:10.2105/AJPH.
2014.302044)
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reproductive-aged women (Table 2). The pri-
mary contributors to STD-related mortality
were HIV (60%) and HPV (34%). During
this interval, a 49% decrease occurred in
the cumulative STD-related mortality rate,
from 5.3 to 2.7 deaths per 100 000 women
(Figure 1).
Between 1999 and 2010 the sexually
acquired HIV mortality rate among women
aged 15 to 44 years decreased by 62%, from
3.4 deaths per 100 000 women in 1999 to
1.3 deaths per 100 000 women in 2010.
The mortality rate from HPV-associated gyne-
cologic cancers (cervical, vulvar, and vaginal)
decreased by 19%, from 1.6 deaths per
100 000 women in 1999 to 1.3 per 100 000
women in 2010 (Figure 1).
Acute viral hepatitis B and hepatitis C in-
fections are sexually acquired about 26%
and 9% of the time, respectively.9---17 Although
the primary infection for sexually acquired
TABLE 1—ICD-10 Code Designation and Estimates for Proportion Attributable to Sexual Transmission for Selected Diseases:
United States, 1999–2010
Disease ICD-10 Code Sexually Transmitted, % Range, %
Viral hepatitis B B16, B18, B18.1 26 22–336–10
Viral hepatitis C B17.1, B18.2 9 6–157,11–14
Hepatocellular carcinoma C22 10 8–1215,16
Chronic liver disease K74 5 4–82,17
Chlamydia trachomatis A56 100 . . .
Neisseria gonorrheae A54 100 . . .
Pelvic inflammatory disease N70–N76 65 40–9018–20
Ectopic pregnancy O00 4321 43–7221–24
HIV B20–B24 80 70–9025–27
Genital herpes A60, B00 100 . . .
Cervical cancer C53 10028–30 . . .
Vulvar and vaginal cancer C51, C52 5031 . . .
Syphilis A50–A53 100 . . .
Other (lymphogranuloma venereum, chancroid, granuloma inguinale,
trichomoniasis, anogenital warts, other predominantly sexually
transmitted disease not elsewhere classified)
A55, A57–A59, A63, A64 100 . . .
Note. HSV = herpes simplex virus; ICD-10 = International Classification of Diseases, 10th revision.5
TABLE 2—Sexually Transmitted Disease–Related Deaths in Reproductive-Aged Women: United States, 1999–2010

















1999 2071 993 139 3 27 9 24 3 1 3270
2000 2043 995 138 3 24 12 19 3 1 3238
2001 1942 977 135 2 23 10 30 4 0 3122
2002 1898 941 145 3 25 8 21 3 1 3045
2003 1782 892 130 1 23 12 17 2 0 2858
2004 1702 900 117 1 17 7 21 4 0 2768
2005 1548 845 118 1 14 8 20 5 0 2558
2006 1463 864 101 0 17 7 16 5 0 2472
2007 1330 890 96 0 16 7 15 4 0 2358
2008 1149 820 90 1 14 9 8 1 0 2092
2009 965 787 81 0 20 10 19 3 0 1885
2010 787 779 82 1 13 10 13 0 0 1684
Total 18 679 10 680 1371 16 233 110 223 37 3 31 351
Note. HPV = human papilloma virus.
Source. Centers for Disease Control and Prevention.4
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hepatitis B virus and hepatitis C virus is com-
monly acquired during a woman’s reproduc-
tive years, morbidity and mortality may occur
much later in life. Hepatocellular carcinoma
and chronic liver disease are severe complica-
tions of chronic hepatitis B and C infections. I
estimated that hepatocellular carcinoma was
caused by hepatitis B virus in 32% of cases and
hepatitis C virus in15% of cases.18,19 I assumed
that nonalcoholic chronic liver disease was
caused by hepatitis B virus in 11% of cases and
hepatitis C virus in 26% of cases.3,20 Accord-
ing to these estimates, the mortality rate from
sexually acquired hepatitis and sequelae de-
creased from 0.2 deaths per 100 000 women
in 1999 to 0.1 deaths per 100 000 women in
2010 (Figure 2).
Chlamydial and gonococcal infections are
not commonly reported as a cause of death, but
these pathogens are associated with PID and
ectopic pregnancy. Approximately 65% of PID
cases are attributable to 1 or both of these
sexually transmitted pathogens.27---31 I estimated
that 43% of ectopic pregnancies are attributable
to chlamydial or gonococcal infection.25---28
Between 1999 and 2010, 65% of chlamydial
and gonococcal infection---related deaths oc-
curred in the setting of PID, and 31% were in
the setting of ectopic pregnancy. The overall
mortality rate from chlamydial and gonococcal
infections, PID, and ectopic pregnancy was
less than 0.1 deaths per 100 000 women in
women aged15 to 44 years. The median number
of deaths was 28 per year (range=23---40).
Syphilis-associated death among reproductive-
aged women in the United States was rare.
Between 1999 and 2010 a total of 37 women
died from syphilis. The number of deaths re-
mained stable with a median of 3 deaths per
year (range = 0---5).
Between 1999 and 2010 a total of 223
reproductive-aged women had genital herpes
simplex virus---associated deaths. The overall
number of deaths each year remained stable,
with a median of 19 deaths per year (range =
8---30).
DISCUSSION
With federal data on multiple causes of death
and the number of women of reproductive age,
I have demonstrated decreasing STD-related
mortality rates among reproductive-aged
women over the past decade. In 1999, STD-
related mortality accounted for 6% of total
mortality among reproductive-aged women.
By 2010, only 4% of mortality in this age
group was attributable to sexually transmitted
infections.4
In 2010, approximately 300 000 women
in the United States were living with HIV in-
fection. Between the years 1999 and 2010,
70% to 90% of new diagnoses of HIV among
women were sexually acquired. This estimate
varies by population demographic and year.24--26
The previous increase in HIV-related mortality
documented by Ebrahim et al. was not ob-
served during 1999 to 2010.3 This was likely
because of the widespread application of highly
active antiretroviral therapy.
More than 40 types of HPV can infect the
genital area. Infection with high-risk, oncogenic
HPV types, such as 16 and 18, increase a
woman’s risk of anogenital cancer.32 The
prevalence of high-risk HPV in the United
States was 23% per a 2003 to 2005 report.33
The highest prevalence was among reproductive-
aged women. Because non---HPV-associated
cervical cancer among reproductive-aged women
is rare, cervical cancer in this age group is
considered entirely attributable to sexually
acquired high-risk HPV infection.28---30 High-
risk HPV causes approximately 50% of vulvar
and vaginal cancers.32 In 2010, mortality data
from the CDC demonstrated that about 17%
of all cervical cancer deaths occurred among
women of reproductive age. The majority of
cervical cancer deaths in 2010 occurred in
women older than 45 years.4 Cervical cancer
screening programs, with consequent earlier
detection and treatment, may have contributed
to the decrease in cervical cancer mortality
among younger women.34
In 1975, the mortality rate from PID was
0.29 deaths per 100 000 women aged 15
to 44 years.1 The PID mortality rate has de-
creased by 90% over the past 35 years to
just a few deaths per year. This dramatic
improvement is presumably because of
continued efforts for chlamydia and gonorrhea
Note. HPV = human papilloma virus.
FIGURE 1—Annual sexually transmitted disease–related mortality in women aged 15–44
years: United States, 1999–2010.
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screening, early diagnosis, and multiple-drug
therapy.32
This analysis has both strengths and weak-
nesses. Among the strengths is the use of
federal, population-based data for the United
States. I included the predominant contributors
to STD-related death, offering a comprehen-
sive assessment of STD-related mortality in
reproductive-aged women. This study also has
several weaknesses. Estimating the contribu-
tion of some infections, particularly hepatitis B
and C, to STD-related mortality is difficult.
The proportion of diseases that are sexually
transmitted likely varies temporally and geo-
graphically. I relied on the estimates used in
previous analyses and the available literature.7--14
Using the attributable proportion of sexual
transmission to estimate mortality from disease
is necessarily imprecise.
Population mortality data from death cer-
tificates are inherently at risk for misclassifica-
tion and underreporting.35 The natural history
of a disease may affect whether reporting
will change over time. A disease that is more
lethal will likely be more frequently reported
as an underlying cause of death. However,
a disease that is less lethal is likely to be under-
reported.35 In 1999, mortality data were
reported on the basis of ICD-10 codes, a change
from previous years. It is unknown whether
medical examiners were less likely to report an
underlying cause of death in 2010 as com-
pared with 1999. Overall, all estimates should
be viewed with caution. Although some mis-
classification is inevitable, this is unlikely to
have changed substantially over time. Hence,
I believe that these temporal trends are real
and not because of artifacts of reporting.
To calculate the percentage of diseases at-
tributable to sexual transmission, I used the
same estimates as those in previous analyses.
This approach informs changing mortality over
time. The methodological issues of this analysis
are unlikely to have accounted for the large
decreases in deaths observed, particularly among
the primary contributors to STD-related mor-
tality from 1999 to 2010: HIV and HPV-related
genital cancer.
My results are useful as estimates of STD-
related mortality to compare with previous
mortality analyses.1,3 The next step, an analysis
of STD-related morbidity for 1999 to 2010
would be achieved by calculating disability-
adjusted life-years.2 The likelihood of sexual
acquisition, morbidity, and mortality from se-
lected diseases may be different among certain
subgroups. Future analyses should evaluate
temporal trends in the disability-adjusted life-
years lost because of STD and identify partic-
ularly vulnerable groups of women.
Although I have described an important
reduction in STD-related mortality among
reproductive-aged women in the United States,
I did not address deaths of children from
perinatal acquisition of STDs. Diseases that are
prevalent in women of reproductive age, such
as N. gonorrheae, C. trachomatis, and genital
herpes, are associated with STD-related neo-
natal complications from preterm birth, cho-
rioamnionitis, and disseminated infection.36---39
On the other hand, mortality from perinatal
HIV transmission will presumably have de-
creased over the past decade because of peri-
natal screening and treatment.40 Less prevalent
conditions, such as syphilis, also have severe
consequences. For example, the CDC reported
431 congenital syphilis cases, and 25 case-
related stillbirths, in 2008.41 Future analyses
should describe STD-related mortality among
neonates over the past decade.
All STD-related deaths are preventable. De-
spite the steady decrease in STD-related deaths
among US reproductive-aged women from
1999 to 2010, the fact that more than 1000
women still die of STD each year underscores
the need for sustained efforts to maintain and
strengthen STD control. Currently, the pre-
dominant contributors to STD-related mortal-
ity among reproductive-aged women are HIV
and HPV-related genital cancers. Behavioral
interventions target high-risk groups to prevent
HIV transmission. Improving HPV vaccine cov-
erage is the key to HPV-related cancer preven-
tion but has been far below goals.42 Efforts to
increase STD prevention should be continued. j
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